Session » Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)

Date: Saturday, November 6, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 0301

Activation of Akt Signaling Pathway in the Minor Salivary Glands of Patients with Primary Sjögren’s Syndrome Does Not Relate with Clinical Phenotype

8:30AM-10:30AM: Abstract Number: 0306

Allergic Disorders in Primary Sjögren’s Syndrome Compared with Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 0305

Artificial Neural Networks Approaches to Predict Myocardial Fibrosis in Primary Sjögren Syndrome Patients Without Cardiac Symptoms

8:30AM-10:30AM: Abstract Number: 0319

Assessment of EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains in Routine Clinical Practice in an Integrated Delivery Network in the United States

8:30AM-10:30AM: Abstract Number: 0307

Cerebellar Ataxia in Primary Sjogren’s Syndrome, Is Gluten Sensitivity the Answer?

8:30AM-10:30AM: Abstract Number: 0318

Correlation Between Prognostic Nutritional Index and Primary Sjögren’s Syndrome Disease Activity

8:30AM-10:30AM: Abstract Number: 0297

Describing the Disease Burden of Primary Sjögren’s Syndrome Patients: Results from a Real-World Survey in the US

8:30AM-10:30AM: Abstract Number: 0313

Do Primary Sjögren’s Syndrome Patients with Normal Major Salivary Gland Ultrasound Have Less Active Disease?

8:30AM-10:30AM: Abstract Number: 0316

Exploring Alternative Responder Definitions for EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) for Use in Sjögren’s Clinical Trials

8:30AM-10:30AM: Abstract Number: 0303

Extraglandular Manifestations as Initial Presentation in a Cohort of Patients with Primary Sjögren’s Syndrome

8:30AM-10:30AM: Abstract Number: 0322

Histopathological Changes in Parotid and Labial Salivary Gland Tissue in Primary Sjögren’s Syndrome Patients After Abatacept Treatment

8:30AM-10:30AM: Abstract Number: 0310

Histopathology, Salivary Flow and Ultrasonography of the Parotid Gland: Three Complementary Measurements in Primary Sjögren’s Syndrome

8:30AM-10:30AM: Abstract Number: 0302

Loss of TAM Receptor Mer Contributes to Sjögren’s Syndrome–like Disease in Mice

8:30AM-10:30AM: Abstract Number: 0309

Lymphopenia and Leukopenia in Sjogren Syndrome

8:30AM-10:30AM: Abstract Number: 0317

Patient and Physician Perspectives on EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) and EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI): A Qualitative Interview Study

8:30AM-10:30AM: Abstract Number: 0320

Performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), an Adjusted ESSDAI Score, in Two Randomised Clinical Trials in Patients with Primary Sjögren’s Syndrome

8:30AM-10:30AM: Abstract Number: 0312

Prognostic Value of Salivary Gland Ultrasonography in Primary Sjögren’s Syndrome

8:30AM-10:30AM: Abstract Number: 0314

PROMIS Provides a Broad Overview of Health-Related Quality of Life in the Evaluation of Sjogren’s Syndrome

8:30AM-10:30AM: Abstract Number: 0304

Renal Involvement in Sjőgren’s Syndrome: Predictors and Impact on Patient Outcome

8:30AM-10:30AM: Abstract Number: 0300

Salivary Gland Epithelial Cells Transcriptomic Analysis Highlight Their Potential Involvement in Extracellular Matrix Modification in Sjögren’s Syndrome

8:30AM-10:30AM: Abstract Number: 0321

Sequential Administration of Belimumab and Rituximab in Primary Sjögren’s Syndrome Reduces Minor Salivary Gland–Resident B Cells and Delays B-Cell Repopulation in Circulation

8:30AM-10:30AM: Abstract Number: 0299

Sex Hormones and Risk of Sjögren’s Syndrome: Hypothesis Generating Findings Implicating Androgen and Estrogen Ratios

8:30AM-10:30AM: Abstract Number: 0315

Sjögren’s Syndrome Symptom Diary (SSSD) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) as Assessments of Symptoms in Sjögren’s Syndrome: A Qualitative Exploration of Content Validity and Meaningful Change

8:30AM-10:30AM: Abstract Number: 0308

Sleep Disorders and Serum Brain-derived Neurotrophic Factor Levels in Patients with Primary Sjögren’s Syndrome

8:30AM-10:30AM: Abstract Number: 0298

The Clinical Phenotype of Isolated Ocular and Oral Dryness in Sjogren Syndrome, Fulfilling the 2016 ACR-EULAR Classification Criteria

8:30AM-10:30AM: Abstract Number: 0296

The Impact of Delayed Primary Sjögren’s Syndrome Diagnosis on Patient Outcomes: A Real-World Survey in the US

8:30AM-10:30AM: Abstract Number: 0311

Ultra High‐frequency Ultrasound (UHFUS) of Labial Glands in Primary Sjögren’s Syndrome: Serological and Histological Correlations

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].